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Abstract 
Splenectomy  and  splenic  irradiation  (SI)
are  the  sole  treatment  modalities  to  control
drug resistant splenomegaly in patients with
myelofibrosis (MF). SI has been used in poor
surgical candidates but optimal total dose and
fractionation  are  unclear.  We  retrospectively
reviewed  14  MF  patients  with  symptomatic
splenomegaly. Patients received a median of
10 fractions in two weeks. Fraction size ranged
from 0.2-1.4 Gy, and total dose varied from 2-
10.8 Gy per RT course. Overall results indicate
that 81.8% of radiation courses achieved a sig-
nificant spleen reduction. Splenic pain relief
and gastrointestinal symptoms reduction were
obtained in 94% and 91% of courses, respec-
tively. Severe cytopenias occurred in 13% of
radiation courses. Furthermore patients were
divided in three groups according to the radia-
tion dose they received: 6 patients in the low-
dose group (LDG) received a normalized dose
of 1.67 Gy; 4 patients in the intermediate-dose
group (IDG) received a normalized dose 4.37
Gy; the remaining 4 patients in the high-dose
group (HDG) received a normalized dose of 9.2
Gy. Subgroup analysis showed that if no differ-
ences in terms of treatment efficacy were seen
among dose groups, hematologic toxicity rates
distributed  differently.  Severe  cytopenias
occurred in 50% of courses in the HDG, and in
the  14.3%  and  in  0%  of  the  IDG  and  LDG,
respectively. Spleen reduction and pain relief
lasted for a median of 5.5 months in all groups.
Due to the efficacy and tolerability of the low-
dose irradiation 4 patients from the LDG and
IDG were retreated and received on the whole
12 RT courses. Multiple retreatments did not
show decremental trends in terms of rates of
response to radiation nor in terms of duration
of  clinical  response.  Moreover,  retreatment
courses  did  not  cause  an  increased  rate  of
adverse  effects  and  none  of  the  retreated
patients experienced severe hematologic toxi-
cities. The average time of clinical benefit in
retreated  patients  was  much  longer  (21
months, range 44-10) than patients who were
not retreated (5.75 months, range 3-6). 
Introduction 
Primary  myelofibrosis
1 (PM)  is  a  Phila-
delphia  negative  chronic  myeloid  disorder
(CMD) currently classified with polycythemia
vera (PV) and essential thrombocythemia (ET)
as  a  chronic  myeloproliferative  disease
2
(MPDs). PM is a rare disease mainly affecting
older people
3 with a median survival of 3.5-5
years.
4 The  pathogenetic  mechanism  is  not
clearly  understood  but  probably  relates  to  a
clonal stem-cell disorder that leads to ineffec-
tive  erythropoiesis,  dysplastic  megakaryocyte
hyperplasia and an increased ratio of imma-
ture to total granulocytes.
5 These findings are
characteristically  accompanied  by  reactive
bone marrow (BM) fibrosis that develops and
is  mediated  by  megakaryocyte-derived  fibro-
genic cytokines.
6
Collagen  fibrosis,  presumably  along  with
many  other  factors,  interferes  with  normal
hematopoietic processes, ultimately leading to
erythroid hypoplasia.
7,8 Due to BM fibrosis, in
MF patients as well as those with post ET/PV
MF, an extramedullary hematopoietic process
starts in the spleen or in multiple organs as an
attempt to override BM failure, often leading to
the  development  of  splenomegaly  or
hepatosplenomegaly.  Moreover,  splenomegaly
exacerbates cytopenias through the sequestra-
tion  and  destruction  of  hematopoietic  ele-
ments.
9
Progressive  high-grade  splenomegaly
occurs  in  the  majority  of  MF  patients.
Unfortunately the standard current pharmaco-
logical therapeutic options, due to their short
periods  of  response,  fail  to  control  organo-
megaly  and  organomegaly-associated  symp-
toms (abdominal pain and early satiety, weight
loss,  portal  hypertension  and  profound
fatigue),  which  account  for  much  of  the
patient’s discomfort. Also even though a new
generation  of  “target  drugs”  are  currently
under intense investigation with some encour-
aging  results,  splenomegaly  control  still
remains a crucial step for patients’ quality of
life improvement.
To date, splenectomy or splenic irradiation
(SI) are the sole treatment modalities to con-
trol  drug  resistant  splenomegaly  in  MF
patients. When technically achievable splenec-
tomy  is  currently  the  preferred  treatment
modality for MF based upon good, long-lasting
outcome  in  term  of  organomegaly-related
symptom palliation.
9,10 Unfortunately, it is con-
sistently associated with a significant rate of
mortality as well as intra- and peri-operative
complications.
9,10 SI, instead, has been general-
ly preferred in patients not undergoing surgery
due to a poor general status or decline and
allows for a good but transitory splenomegaly
palliation.  In  fact,  the  major  shortcoming  of
radiation  is  that  its  palliative  effect  on
splenomegaly  generally  does  not  last  longer
than six months. 
There is a general agreement that emerges
from the literature to use RT at dose levels
lower than in other hematologic malignancies;
however, few studies have taken a retrospec-
tive look at SI.
11 The indication for SI is still
controversial
12 and  there  is  not  a  precise
unequivocal  definition  of  the  optimal  total
dose and fractionation, mainly due to the lim-
ited number of patients included in existing
studies and the wide range of radiation sched-
ules adopted. Moreover, it is unclear if re-irra-
diation  of  MF  patients  is  a  safe  strategy  to
extend the overall time of clinical benefit that
a  single  SI  course  allows.  Here  we  aim  to
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assess  outcomes  and  complication  rates  of
splenic irradiation in three cohorts of patients
treated  with  different  “low-dose”  irradiation
schedules. 
Patients and Methods  
After  approval  from  our  institutional
research review committee, we retrospectively
reviewed  data  concerning  15  patients  (10
male, 5 female, median age at diagnosis 61
years, median age at first irradiation 67 years),
11 with a histologically proven diagnosis of PM
and 4 with a post ET-MF complaining of a high-
grade  symptomatic  splenomegaly  that  were
consecutively referred to our institution from
1997-2007 (Table 1). All patients had a drug
resistant splenomegaly and lacked any further
treatment  options.  Before  being  admitted  to
radiation, patients had previously been judged
unfit for surgery due to their general status or
had refused splenectomy. Fourteen out of 15
underwent  splenic  irradiation  and  one  was
excluded due to pre-existing advanced heart
failure  (patient  14).  In  the  14  irradiated
patients the first course of radiation occurred
at a median of 58 months from the diagnosis of
MF.  All  14  treated  patients  had  a  severe
splenomegaly  with  splenic  pain,  abdominal
discomfort, and weight loss; 11 patients (84%)
had  in  concurrence  constitutional  symptoms
such as night sweats, low-grade fever and an
initial state of cachexya. All except 3 required
red  blood  cell  transfusions  (≥2  units  per
month).  
Patients were scored (at the time of their
first  irradiation)  on  the  basis  of  Dupriez’s
prognostic  parameters
13 (Hb  levels  <10  g/dL
Land  WBC  <4  or  >30ￗ10
9/L)  in  three  cate-
gories: high- , intermediate- and low-risk. Four
patients belonged to the high-risk, 4 to the low-
risk  and  6  to  the  intermediate-risk  groups,
respectively.  All  patients  had  already  under-
gone  a  cytoreductive  pharmacological  treat-
ment:  8  received  hydroxyurea  as  a  single
modality treatment, one received hydroxyurea
plus  Ara-C,  2  patients  received  hydroxyurea
plus 6-mercaptopurine, one received hydrox-
yurea and melphalan, one received busulphan
and 3 patients were given thalidomide in asso-
ciation with conventional cytoreductive treat-
ments. Radiation treatment was delivered by a
Siemens 15 MV Linac with multi leaf collima-
tor; all patients had a CT scan simulation (slice
thickness 10 mm) in the supine position. The
treatment  planning  system  (Plato  system  v
2.6.3.) was used and no patient immobilization
devices  were  adopted  during  the  simulation
and treatment. 
Two portal arrangements were alternatively
used to encompass the entire spleen volume:
antero-posterior (AP-PA), opposed parallel or
opposed tangential in the attempt to reduce
the dose to the left kidney. If the left kidney
was  displaced  posteriorly,  a  tangential
arrangement was provided; if the kidney was
displaced  medially  an  antero-posterior
approach was arranged. In the planned evalua-
tion process between target coverage and kid-
ney sparing we assigned priority to left kidney
sparing in order to reduce the total dose to the
organ in case of multiple courses of splenic
irradiation.  
Since our institutional standards of radia-
tion for MF have changed during the past ten
years, patients received different total doses
and dose per fraction. To compare the various
RT treatments we used the Normalized Tumor
Dose
14 (NTD10), defined as the total dose deliv-
ered in 2 Gy fractions that corresponds to a
particular biologically effective dose level and
is calculated according to the formula: 
where n is the number of RT fractions and d
the fraction size in Gy. The α/β value of the
Linear Quadratic Model
15 was empirically fixed
to 10 as for early responding tissues. By stan-
dardizing the delivered dose of all 22 adminis-
tered treatments into a 2 Gy isoeffective treat-
ment, we were able to make a correct radiobi-
ological  comparison  among  different  RT
schedules.  On  the  basis  of  the  NTD  values,
patients  were  divided  into  three  different
groups  but  it  should  be  underlined  that  RT
schedules  were  not  chosen  on  the  basis  of
patients’ clinical parameters but rather were
dependent on the progressive modification of
our institutional treatment philosophy.  
The initial patients, who had received a total
dose of 10 Gy with a dose per fraction in the
order of 1 Gy, were designated as our high-
dose group (HDG). Patients who had received
our current standard of treatment (0.2 Gy frac-
tion up to a total dose of 2 Gy in 10 fractions)
Table 1. Patients’ characteristics at the time of first irradiation.
Patient N. Age at  Interval Dupriez  Previous  Symptoms  RBC  Pre- Pre-
irradiation diagnosis score treatments at time transfusion irradiation WBC irradiation PLT
and sex irradiation of radiation U/month ￗ10
9/L ￗ10
9/L
(intent to treat)
1* 53 F 14 y. HR HU S , P 2U 39.9 232
2* 65 F 16 y. IR HU S , P, CS 4U 6.48 381
3 62 F 3 y. LR HU; MPH  S , P 2U 9.55 21
4* 75 F 8 y. LR HU S , P, CS 2U 8.36 44
5 67 M 4 y. IR HU S , P, CS 2U 5.7 210
6 67 M 8 y. IR HU; Ara-C  S , P NT 38.1 190
7 77 M 8 y. LR HU; 6-MP S , P, CS 2U 10.3 423
8 87 M 1 y. HR B; Th S , P, CS 2U 2.63 119
9 46 M 4 y. IR HU S , P, CS NT 29.6 307
10 67 M 1 y. IR HU S , P, CS 2U 4.9 121
11 70 M 2 y. HR HU S , P, CS 2U 89 143
12 58 M 7 y. LR HU; Th S , P,  night sweats NT 10.89 329
13* 65 M 2 y. IR HU; 6-MP; Th S , P, CS 2U 8 673
14 76 M 4 y. HR HU S , P, CS 4U 1.04 67
15 55 F 4 y. HR HU; Th S , P, CS 2U 42.51 143
S: Splenomegaly; P: splenic pain; CS: constitutional symptom; HU: Hydroxyurea; Th: Thalidomide; 6-MP: 6-Mercaptopurine; ARA-C: Arabinosylcytosine; MPH: Melphalan; B: Busulphan; HR: High-risk; 
IR: Intermediate-risk; LR: Low-risk; NT:Not transfused.*Post ET - MF.Table 2. Splenic irradiation results (by NTD group).
Number of patients Median   Number  Median Dose  NTD10 Response
PM Post  dose  of courses per fraction m sd % of courses  % of courses  Median duration Hematologic  
ET MF delivered with reduction  with pain relief of response toxicity
in spleen size (in months) Grade 4
RTOG
LDR 33 200 cGy 11 20 cGy 1.67 Gy 0.60 91% 100% 6 months 0%
(2-4 Gy range) (range 3-12)
HDR 40 1000 cGy 4 110 cGy 9.20 Gy 0.46 75% 100% 4 months 50%
range (range 6-0) ( 2/4 )
(980-1080cGy)
IDR 31 500 cGy 7 50 cGy 4.37 Gy 1.89 76.5% 86% 5 months 14.3%
Range (range 6-0) (1/7 )
(300-800 cGy)
Low-dose group (LDG); high-dose group (HDG); intermediate-dose group (IDG); median (m) standard deviation (sd).
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were designated as our low-dose group (LDG).
Whereas  the  intermediate-dose  group  (IDG)
reflected  the  transition  or  better  our  “dose
finding effort” toward lower doses with the aim
to  reduce  treatment  related  toxicities
(Supplementary Tables). The IDG encompass-
es patients who had received a wide range of
treatment with radiobiological characteristics,
which,  in  some  cases,  may  partially  overlap
with the LDG. However, we decided to aggre-
gate our patients in this way in order to obtain
homogeneity in the low- and in the high-dose
groups.  
Patients in which three or more of the fol-
lowing criteria were present were considered
responsive to treatment: subjective absence of
MF-related  gastrointestinal  symptoms  (bulky
effect),  absence  of  splenic  pain,  consistent
reduction of the spleen volume (not less than
50%  of  the  initial  size)  assessed  by  clinical
examination (according to the formula: spleen
volume = 4/3ˀ 1° diameter ﾰ 2° diameter ﾰ 3°
diameter) and, finally, reduction of the RBC
transfusion units required per month. 
To evaluate toxicity and response to treat-
ment, patients had undergone clinical exami-
nation and blood cell count twice a week dur-
ing the period of irradiation and for the follow-
ing two weeks. If no toxicity occurred, blood
tests were scheduled weekly for the following
month. The evaluation of the spleen reduction
was carried out 20 days after patients had com-
pleted radiation.  
Treatment  related  toxicity  was  limited  to
myelosuppression and was measured on the
basis of RTOG acute toxicity scoring criteria.
An  RT  course  after  which  a  post-radiation
grade  4  (WBC  count  ≤1ￗ10
9/L  and/or  PLTs
count ≤20ￗ10
9/L) acute cytopenia had devel-
oped was considered too toxic. RBC count was
excluded from toxicity scoring because almost
all  patients  were  already  heavily  transfused
long before receiving RT. Due to the small size
of the study cohort and the lack of homogene-
ity in patients’ characteristic due to the accru-
al criteria, we did not perform any statistical
data analysis, as it would not be statistically
representative or pertinent.  
Results 
Total delivered dose per RT course ranged
from 2 to 10.8 Gy, the dose per fraction varied
from  0.2-1.4  Gy.  RT  courses  were  generally
administered over a two week period (median
number  of  fraction  per  RT  course  was  10),
patients received RT five days per week contin-
uously; 4 patients had multiple courses of RT,
and one patient received 4 courses. In the first
group  (low-dose  group,  LDG),  6  patients
received a median NTD of 1.67 Gy (0.6 stan-
dard deviation). In the second (intermediate-
dose  group,  IDG),  4  patients  had  a  median
NTD of 4.37 Gy (1.89 standard deviation). The
third group (high-dose group, HDG) contained
4 patients who received a normalized median
dose of 9.2 Gy (0.46 standard deviation). 
According to the above-defined criteria, 12
patients were considered responsive. Overall
response rates after all 22 RT treatments indi-
cate that 81.8% of courses achieved a signifi-
cant  spleen  size  reduction;  however,  better
results  were  achieved  on  splenic  pain  relief
(94.45% of RT courses) and reduction of gas-
trointestinal symptoms (91% of courses). No
significant difference in terms of spleen size
reduction and splenic pain relief emerged after
subgroup  analysis.  Patients  in  the  LDG  had
spleen size reduction and splenic pain relief in
91% and 100% of courses, respectively, while
in the IDG and in the HDG, 76.5% and 75% of
courses obtained a spleen size reduction. Pain
relief was achieved in 86% and 100%, respec-
tively (Table 2). 
After  completing  radiation  all  responsive
patients  had  an  improvement  in  their  body
weight while SI was less effective in reducing
patients’  transfusion  requirements.  In  only
35.3%  (6/17)  of  courses  there  was  a  slight
improvement  of  anemic  state,  but  this  was
transient and shorter than spleen size reduc-
tion and pain relief.  
Within the entire study population, grade 4
RTOG life-threatening cytopenias occurred in
21.5 % of patients (3/14) or 13.6% of RT cours-
es. In all cases it developed in the first week
after completing radiation and required hospi-
talization. Interestingly, RT complications dis-
tributed differently among groups. In the LDG,
no  grade  4  RTOG  adverse  effects  occurred.
Patients in the IDG experienced 14.3% of RT
courses  followed  by  severe  cytopenias  (1/  7
courses), while in the HDG, 50% of RT treat-
ments were too toxic (Supplementary Figure
1). Both non-responding patients (patients 9
and  8)  experienced  severe  acute  complica-
tions. One (patient 8) appeared to have been
rescued from cytopenia but three months later
developed a leukemic transformation that led
to death. The second patient (patient 9), com-
plained  of  a  massive  splenomegaly,  did  not
respond to SI and underwent splenectomy 12
months after RT. One month after splenectomy
the patient died as a result of sepsis. 
The median time of symptom relief after a
single RT course was 5.5 months and no differ-
ences  were  found  among  dosage  groups.
According to the patients’ general conditions,
the cumulative RT dose delivered and the rate
of spleen shrinkage in response to previous
irradiation, retreatment after splenic relapse
was considered in 4 patients. The 4 retreated
patients received on the whole 12 RT courses
and one patient received 4 courses without any
acute  toxicity.  Two  of  the  retreated  patients
belonged to the LDG and the remaining 2 to
the IDG. However, it is important to note that
ArticleArticle
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of  the  patients  retreated  from  the  IDG,  one
received treatments of 0.3 up to 3 Gy in 10 frac-
tions total, which could be considered radiobi-
ologically partially overlapping with the treat-
ment dosages of the LDG.  
In comparison to the first irradiation, multi-
ple  retreatments  did  not  show  decremental
trends in terms of rates of response to radia-
tion  nor  in  terms  of  duration  of  clinical
response. Even in the case of one patient, who
received 4 RT courses, there was no change in
the  duration  of  symptoms’  palliation.
Moreover, after retreatment courses we did not
observe an increased rate of adverse effects
and none of the retreated patients experienced
severe  hematologic  toxicities.  The  average
time of clinical benefit (Supplementary Figure
2) in retreated patients was very much longer
(21 months, range 44-10) than patients who
were not retreated (5.75 months, range 3-6). 
Discussion 
Splenomegaly  rapidly  occurs  in  all  MF
patients and is one of the causes of major dis-
comfort. Curative treatments are to-date still
limited in MF. Allogenic bone marrow trans-
plantation  (allo-BMT)  has  shown  promising
results in younger patients but its role in eld-
erly patients is controversial. In particular, sev-
eral studies suggest that in individuals older
than 45 the treatment’s risk-related mortality
outweighs  the  benefits.
16 On  the  contrary,
other studies more recently explored the use
of allo-BMT also in patients older than 60 with
some interesting results.
17,18 Currently, BMT in
the elderly is still a matter of debate since the
number of patients accrued in clinical trials is
limited and the follow-up time short. Since MF
remains a disease of the elderly, standard and
palliative  treatments  to  manage  cytopenias
and massive organomegaly still retain a rele-
vant role in a consistent proportion of patients.  
Splenomegaly can be effectively controlled
by conventional cytotoxic chemotherapy
19 until
patients become drug resistant. More recently
atiangiogenic  drugs  and  target  drugs  are
expected to offer a new chance of treatment
for all patients. In particular a new class of
molecules designed to inhibit Jak have been
tested in different phase II trials with positive
results.
20 Jak inhibitors have shown a signifi-
cant activity on splenomegaly but there is no
reason to think that, along with their use, also
resistant patients will be selected. 
After massive splenomegaly is established,
splenectomy is considered the principle pallia-
tive measure because it offers a lengthy relief
of  symptoms.  Unfortunately  splenectomy  is
weighted by significant morbidity and mortali-
ty  rates.  The  two  largest  single  institution
series  from  Barosi
10 and  Tefferi
9 reported  a
mortality  rate  of  8.4%  and  9%,  respectively,
with  the  latter  increasing  to  26%  when  the
three-month post-splenectomy period was con-
sidered,  and  a  morbidity  rate  of  39.3%  and
31%, respectively. After splenectomy, up to 25%
of  patients  may  experience  accelerated
hepatomegaly  and  extreme  thrombocytosis.
21
Moreover, splenectomy has also been correlat-
ed to a significantly higher incidence of blast
transformation.  
A large Italian study demonstrated a crude
transformation  rate  in  splenectomized
patients of 26.4% in comparison to 11.9% in
non-splenectomized patients with the cumula-
tive  actuarial  transformation  rate  of  55%  in
splenectomized vs.27% in non-splenectomized
patients at 12 years after diagnosis. The over-
all  relative  risk  of  blast  transformation  was
therefore  2.61  times  higher  among  splenec-
tomized patients.
22 In conclusion, despite the
impact on symptoms, no overall survival bene-
fit has been demonstrated after splenectomy
9,23
on the contrary, this procedure is associated
with a substantial risk of operative mortality,
early and late morbidity and is contraindicated
in patients with thrombocytosis. Furthermore,
splenectomy has been shown to be a predictor
of  treatment  failure  in  case  of  allo-BMT.
16
Alternative  treatments  to  manage
splenomegaly, with lower morbidity and mor-
tality rates, would offer a significant improve-
ment  in  the  clinical  management  of  MF
patients.  
Radiotherapy has been used in selected sit-
uations  to  control  extramedullary  hemato-
poiesis,  as  in  spinal  localizations,
24 in  pul-
monary  hypertension
25 or  in  symptomatic
hepatomegaly
26 with  promising  results.
However, its role in splenic palliation remains
controversial because of the lack of robust data
(Table 3). It has been shown that splenic irra-
diation  can  be  very  effective  in  reducing
spleen  size  and  splenic  pain  with  response
rates comparable to splenectomy.
33 The major
shortcoming of radiotherapy is the reliance on
its  transient  effect  that  normally  does  not
exceed six months. 
As  an  alternative  to  splenectomy,  SI  has
been considered in poor surgical candidates or
in  patients  who  declined  surgery.  In  these
patients, that generally are in a worse condi-
tion compared to those that undergo surgery,
palliative splenic irradiation has shown mor-
tality rates that are comparable to splenecto-
my.
27 On the other hand, a high rate of severe
life-threatening cytopenias has been reported
in patients that underwent splenic irradiation,
ranging from 32% (16/50 courses) of the Mayo
Clinic series
27 where lower doses of RT were
used  (median  dose  per  course  2.775  Gy)  to
35% (6/17 courses) of a French series
31 where
a  more  aggressive  treatment  was  delivered
(median dose per course 9.8 Gy). 
Although  a  general  trend  in  favor  of  low
doses is emerging in the literature, the wide
variability of total radiation doses, the differ-
ent number of fractions, as well as the differ-
ent schedule of irradiation reported, makes it
difficult to define a standard of treatment.
33
In order to be able to make dose-effect com-
parisons, the major drawback of some of the
published series is that the total dose and the
fractionation scheme seem not to be decided
up-front from the treatment but modified dur-
ing the irradiation on the basis of the single
patient response with a consequent high vari-
ability in the total dose, fractionation and over-
all treatment time. Some authors
31 used the
common 5 daily fractions per week schedule
but increased the fraction size during the radi-
ation course (from 0.4-0.5 Gy/fraction in the
first week of treatment, up to 0.8-1 Gy/fraction
during the following weeks) until the palliative
effect or toxicity is reached. Other authors
30
give  radiation  2-3  times  per  week  with  an
altered time factor. Both such approaches can
be empirically effective but generate data that
are  difficult  to  compare  with  the  common
radiobiology algorithms that are based on larg-
er daily fraction sizes (around 2 Gy) and with
a time of inter-course sub-lethal DNA damage
repair of 24 hours between fractions.  Given
that it is hard to make radiobiological compar-
isons among some published series, it is clear
that, still now, the most critical issue regard-
ing a rational use of RT is the definition of an
optimal total dose and fractionation.
The leading idea of our approach to SI has
been  to  adopt  a  relative  long  fractionation
schedule of 10 fractions in two weeks inde-
pendent of the total dose delivered with the
intent to generate comparable results, also in
case of treatments differing in total dose and
dose per fraction. This approach should also
minimize  the  incidence  rate  of  post-attinic
severe cytopenias and favor a rapid recovery of
early blood precursors from RT. In fact, since a
strong dose-sparing effect of fractionation on
bone marrow precursors
34,35 has been proven,
we believed that it would be meaningful to also
apply this concept to extramedullary hemato-
poiesis sites. Therefore, we decided to utilize a
long RT schedule (median 10 fractions) even
when it could appear unjustified to do so due
to the minimal total dose delivered.  
Regarding the total dose, at the beginning
of our experience, we adopted an aggressive
RT regimen (1 Gy per fraction up to a total
dose of 10 Gy) but we observed a high inci-
dence of severe side effects. This raised the
concern  that  the  same  stem  clonal  disorder
that underlies MF could make hematopoietic
precursors  more  sensitive  to  radiation.  In
order to reduce the incidence of acute cytope-
nias we progressively reduced total RT doses
until  we  established  our  actual  standard  of
care (0.2 Gy per fraction up to 2 Gy total dose).  
Our findings show that extremely low-dose[Hematology Reviews 2009; 1:e7] [page 37]
treatments  are  isoeffective  as  compared  to
higher dose regimens in effectively reducing
splenomegaly.  Unfortunately,  we  cannot
explain the functionality of low-dose treatment
regimens in being so effective as compared to
high-dose treatments; however, these findings
are in concordance with the hypothesis of low-
dose hypersensitivity.
36 The suggestive issue of
radiobiology  has  been  intensely  investigated
in vitro
37 and postulates a hypersensivity state
of cells when irradiated at low doses (<0.4-0.5
Gy). Recently, there have been several indirect
confirmations of this theory in clinical studies,
linking  low-dose  hypersensivity  to  tumor
regression
38 as  well  as  to  the  occurrence  of
adverse  effects,
39 at  dose  levels  under  the
threshold  generally  accepted  for  toxicity  or
tumor control.  
Since  in  our  series,  as  well  as  in  others
reported,
27-29,31 there is an inherent discrepancy
due to variability in total dose delivered, frac-
tion number, and fraction size, to be able to
correctly  compare  different  treatments  we
used the NTD formula, a radiobiological tool
commonly used in the clinic to evaluate the
biological  effectiveness  of  modified  RT  frac-
tionations.  The  overall  NTD10 of  all  22  RT
courses in our series is 2.59 Gy, a value compa-
rable with the median NTD10 estimated from
the Mayo series (3.16 Gy). Interestingly our
patients seem to have a lower overall incidence
rate of grade 4 RTOG (13.6% of courses vs.
32%). This discrepancy is somehow difficult to
be explained since there are just slight differ-
ences in the normalized radiation dose that
patients  of  the  two  groups  received.  Even  a
slighter difference in terms of patient charac-
teristics can be found between the Mayo Clinic
series and ours (median age at the time of the
first irradiation 65 vs. 67 years; time intercur-
ring between diagnosis and irradiation 44 vs.
58 months, respectively). A possible explana-
tion could be that in the definition of toxicity
criteria, differing from the Mayo report, we did
not  consider  hemoglobin  levels  since  the
majority of our patients were transfused from
a  long  time  before  receiving  radiotherapy.
Another possible explanation could rely on the
medical  treatment  that  patients  received
before undergoing radiation: in fact, it is inter-
esting to note that the only 2 patients in both
series  that  received  melphalan  as  medical
treatment before radiation later experienced
severe post-attinic cytopenias. 
To compare outcomes after different radia-
tion doses we stratified our patients into three
groups  according  to  the  NTD10 value  they
received. We found that, if no differences in
terms  of  spleen  shrinkage  or  pain  relief
emerged among patients who underwent dif-
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Table 3. Synoptic table of published data on palliative SI in myelofibrosis.
Author Number of patients Median   # Median Estimated NTD10 Response
MF Post  dose  of RT  dose Median  Dev  % of courses  % of courses  Median duration
PV/ET  delivered courses per  standard with reduction  with pain of response
fraction in spleen size relief (In months)
Elliot
27 18 5 277.5cGy 50 50 cGy 3,162 Gy 2,784 94% 96% 6
range range
(30-1365 Gy) (1-41)
Greenberger
28 13 1 650 cGy range 21 57.14 cGy 5,807 Gy 3,204 95% 100% NV
(40-1728 cGy) range
(1-73)
Parmentier
29 54 690 cGy range 12 25cGy 5,845 Gy 6,451 92% NA NA
(180-2900 cGy) range
(12,5-75)
Wagner
30 60 NA NA NA NA NA 80% 63% NA
From 200-450 cGy in 25-50  cGy 
fraction 3 times per week
Bouabdallah
31 15 0 980cGy 17 Daily fr.  NA NA 81% 90% Spleen size reduction 
(60-3050 cGy) 40-100 cGy  6 months range
median  (1-24 months)
duration  Splenic pain 7 months
22 days Range (1-19 months)
Mc Farland 
32 42 range 13 Irradiation  NA NA 92% NA MF: 1-16 months
300-600 cGy twice wk: Post PV/MF: 2-12 months
1stw50cGy
2ndw75cGy
3rdw100cGy
Present study
LDG 33 200 cGy 11 20 cGy 1.67 Gy 0.603 91% 100% 6 months
range (range 3-12)
(200-400 cGy)
HDG 40 1000 cGy 4 110 cGy 9.205 Gy 0.465 75% 100% 4 months
range (range 6-0)
(980- 1080 cGy)
IDG 31 500 cGy 7 50 cGy 4.375 Gy 1.892 76,5% 86% 5 months
range (range 6-0)
(300-800 cGy)
NA: not assessable.Article
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ferent RT regimens, daily fractions of 0.2 Gy up
to 2 Gy is significantly the safer fractionation
scheme since it is not associated to grade 4
hematologic toxicities. In our patients, inde-
pendently  from  the  dose,  radiotherapy  was
very  effective  in  reducing  massive
splenomegaly, but did not resolve completely
the  spleen  enlargement  (Supplementary
Tables). It is possible to argue that, since we
found a safe RT schedule, it would be mean-
ingful to prolong the radiation treatment until
a  complete  splenomegaly  remission.  On  the
contrary, we decided to maintain a conserva-
tive approach and to stop the treatment once
the planned final dose was achieved. Two main
considerations led to our decision: first of all
the fact that the palliative effect of radiothera-
py seems to last no longer than six months
independently  from  the  dose  delivered.  We
were concerned that reducing the spleen size
until  normalization  could  result  in  a  small
increase of the time free from symptoms at the
cost of a probably higher incidence of severe
cytopenias.  Secondly,  since  the  aim  of  our
treatment  was  strictly  palliative,  we  consid-
ered it meaningful, once symptom relief was
achieved, to stop the treatment with the intent
to minimize the patient’s absorbed dose per
course of RT in order to potentially be able to
repeat the treatment in the future.
In fact, because of the low incidence of mild
adverse effects in the LDG (and in the lower
dose burden of the IDG) we were able to repeat
the irradiation several times thus prolonging
the clinical benefit much more than expected.  
Four patients safely underwent 12 RT cours-
es with no occurrence of grade 4 RTOG hema-
tologic  toxicity.  All  the  retreated  patients
belong to the low-or intermediate-risk group.
In these patients the intensity and the persist-
ence of splenic response to irradiation did not
change  under  multiple  retreatment  courses.
However,  retreatment  increased  the  average
time of symptoms relief four fold longer than
in un-retreated patients (21 months vs. 5.75).
It could be argued that a possible bias in our
work is that all the post ET-MF patients were
allocated in the LDG or in the inferior burden
of other IDG but this fact could not modify the
consistency of the presented data; especially
because just one patient with post ET-MF has
been  retreated  so  far.  We  propose  that  the
results regarding the average time of clinical
benefit in retreated patients can be considered
substantially  valid  for  primary  MF  patients.
Furthermore, it deserves to be mentioned that,
in comparison to MF patients, a shorter inter-
val  free  from  symptoms  has  been  reported
after SI
32 in post-ET MF patients. 
With  all  the  limitations  inherent  in  the
small number of patients examined, we found
that in our series Dupriez’s score (calculated
at the time of patient’s referral to the radio-
therapy  department)  is  not  predictive  of
response to palliative radiotherapy or occur-
rence of toxicity. We conclude that our actual
standard of 2 Gy delivered in 10 fractions over
two weeks has a NTD of 1.67 Gy, a value two-
to three-fold lower than other published series.
This schedule of treatment has been shown to
be extremely well tolerated and to date in our
experience  is  not  associated  with  severe
hematologic  toxicities.  Such  optimal  treat-
ment compliance encouraged repeating irradi-
ation in responsive patients and this favored a
drastic increase in the average time of clinical
benefit. 
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